Azelnidipine, unique calcium channel blocker could prevent stress-induced cardiac dysfunction like α·β blocker.

Journal of cardiology 20120701

Combined effect of angiotensin II receptor blocker and either a calcium channel blocker or diuretic on day-by-day variability of home blood pressure: the Japan Combined Treatment With Olmesartan and a Calcium-Channel Blocker Versus Olmesartan and Diuretics Randomized Efficacy Study.

Hypertension (Dallas, Tex. : 1979) 20120601

Calcium antagonist added to angiotensin receptor blocker: a recipe for reducing blood pressure variability?: evidence from day-by-day home blood pressure monitoring.

Hypertension (Dallas, Tex. : 1979) 20120601

Mechanistic study on degradation of azelnidipine solution under radical initiator-based oxidative conditions.

Journal of pharmaceutical and biomedical analysis 20120305

Azelnidipine attenuates glomerular damage in Dahl salt-sensitive rats by suppressing sympathetic nerve activity.

Hypertension research : official journal of the Japanese Society of Hypertension 20120301

Azelnidipine is a calcium blocker that attenuates liver fibrosis and may increase antioxidant defence.

British journal of pharmacology 20120201

Capture hydrolysis signals in the microsomal stability assay: molecular mechanisms of the alkyl ester drug and prodrug metabolism.

Bioorganic & medicinal chemistry letters 20120115

Olmesartan medoxomil and azelnidipine therapy in patients with hypertension and chronic kidney disease in Japan.

Journal of nephrology 20120101

Combination therapy of olmesartan and azelnidipine inhibits sympathetic activity associated with reducing oxidative stress in the brain of hypertensive rats.

Clinical and experimental hypertension (New York, N.Y. : 1993) 20120101

Long-term effects of calcium antagonists on augmentation index in hypertensive patients with chronic kidney disease: a randomized controlled study.

American journal of nephrology 20120101

Solid state characterizations and analysis of stability in azelnidipine polymorphs.

Chemical & pharmaceutical bulletin 20120101

Azelnidipine inhibits Msx2-dependent osteogenic differentiation and matrix mineralization of vascular smooth muscle cells.

International heart journal 20120101

Design and rationale of Japanese evaluation between Formula of Azelnidipine and amlodipine add on olmesartan to Get antialbuminuric effect study (J-FLAG) : evaluation of the antialbuminuric effects between calcium channel blocker with sympatholytic action in hypertensive patients with diabetes and albuminuria.

Cardiovascular drugs and therapy 20110801

Additive antioxidative effects of azelnidipine on angiotensin receptor blocker olmesartan treatment for type 2 diabetic patients with albuminuria.

Hypertension research : official journal of the Japanese Society of Hypertension 20110801

L-/T-type Ca channel blockers for kidney protection: ready for sophisticated use of Ca channel blockers.

Hypertension research : official journal of the Japanese Society of Hypertension 20110801

Azelnidipine, a new calcium channel blocker, promotes skin wound healing in diabetic rats.

The Journal of surgical research 20110701

Calcium channel blocker inhibition of AGE and RAGE axis limits renal injury in nondiabetic patients with stage I or II chronic kidney disease.

Clinical cardiology 20110601

Urinary albumin excretion during angiotensin II receptor blockade: comparison of combination treatment with a diuretic or a calcium-channel blocker.

American journal of hypertension 20110401

Reduction of albuminuria with antihypertensive treatment: is more always better?

American journal of hypertension 20110401

Association between aldosterone induced by antihypertensive medication and arterial stiffness reduction: the J-CORE study.

Atherosclerosis 20110301

Co-treatment with azelinidipine and olmesartan inhibits advanced glycation end products (AGEs) elicited down-regulation of adiponectin mRNA levels in cultured adipocytes partly via its anti-oxidative property.

International journal of cardiology 20110121

Comparison of combination therapy of olmesartan plus azelnidipine or hydrochlorothiazide on renal and vascular damage in SHR/NDmcr-cp rats.

Kidney & blood pressure research 20110101

Azelnidipine and amlodipine anti-coronary atherosclerosis trial in hypertensive patients undergoing coronary intervention by serial volumetric intravascular ultrasound analysis in Juntendo University (ALPS-J).

Circulation journal : official journal of the Japanese Circulation Society 20110101

Comparative effects of azelnidipine and amlodipine on myocardial function and mortality after ischemia/reperfusion in dogs.

Journal of pharmacological sciences 20110101

Effects of Azelnidipine plus OlmesaRTAn versus amlodipine plus olmesartan on central blood pressure and left ventricular mass index: the AORTA study.

Vascular health and risk management 20110101

Effects of calcium channel blockers on glucose tolerance, inflammatory state, and circulating progenitor cells in non-diabetic patients with essential hypertension: a comparative study between azelnidipine and amlodipine on glucose tolerance and endothelial function--a crossover trial (AGENT).

Cardiovascular diabetology 20110101

Azelnidipine prevents cardiac dysfunction in streptozotocin-diabetic rats by reducing intracellular calcium accumulation, oxidative stress and apoptosis.

Cardiovascular diabetology 20110101

Anti-leishmanial and anti-trypanosomal activities of 1,4-dihydropyridines: In vitro evaluation and structure-activity relationship study.

Bioorganic & medicinal chemistry 20101115

Azelnidipine-induced chyloperitoneum in a patient with microscopic polyangiitis.

Clinical and experimental nephrology 20101001

Combination therapy of calcium channel blocker and angiotensin II receptor blocker reduces augmentation index in hypertensive patients.

The American journal of the medical sciences 20100501

Effects of combination olmesartan medoxomil plus azelnidipine versus monotherapy with either agent on 24-hour ambulatory blood pressure and pulse rate in Japanese patients with essential hypertension: additional results from the REZALT study.

Clinical therapeutics 20100501

Combination therapy with olmesartan and azelnidipine improves EDHF-mediated responses in diabetic apolipoprotein E-deficient mice.

Circulation journal : official journal of the Japanese Circulation Society 20100401

Cardiovascular effects of azelnidipine in comparison with those of amlodipine assessed in the halothane-anaesthetized dog.

Basic & clinical pharmacology & toxicology 20100201

[Enantiomeric separation of azelnidipine by high performance liquid chromatography with chiral stationary phase].

Se pu = Chinese journal of chromatography 20100201

Azelnidipine, a long-acting calcium channel blocker, could control hypertension without decreasing cerebral blood flow in post-ischemic stroke patients. A 123I-IMP SPECT follow-up study.

Hypertension research : official journal of the Japanese Society of Hypertension 20100101

[Calcium antagonists: current and future applications based on new evidence. Calcium channel blockers and autonomic nervous system].

Clinical calcium 20100101

Beneficial effect of combination therapy comprising angiotensin II receptor blocker plus calcium channel blocker on plasma adiponectin levels.

Clinical and experimental hypertension (New York, N.Y. : 1993) 20100101

Plasma renin activity and aldosterone concentration are not altered by the novel calcium channel antagonist, azelnidipine, in hypertensive patients.

Internal medicine (Tokyo, Japan) 20100101

Anti-inflammatory properties of azelnidipine, a dihydropyridine-based calcium channel blocker.

Clinical and experimental hypertension (New York, N.Y. : 1993) 20100101

Cytokine reducing effect of azelnidipine in human peripheral blood mononuclear cells.

Biological & pharmaceutical bulletin 20100101

Azelnidipine and amlodipine: a comparison of their effects and safety in a randomized double-blinded clinical trial in Chinese essential hypertensive patients.

Clinical and experimental hypertension (New York, N.Y. : 1993) 20100101

Azelnidipine protects myocardium in hyperglycemia-induced cardiac damage.

Cardiovascular diabetology 20100101

Azelnidipine exerts renoprotective effects by improvement of renal microcirculation in angiotensin II infusion rats.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20091201

A randomized, double-blind, four-arm parallel-group study of the efficacy and safety of azelnidipine and olmesartan medoxomil combination therapy compared with each monotherapy in Japanese patients with essential hypertension: the REZALT study.

Hypertension research : official journal of the Japanese Society of Hypertension 20091201

Angiotensin-II receptor antagonist combined with calcium channel blocker or diuretic for essential hypertension.

Hypertension research : official journal of the Japanese Society of Hypertension 20091101

Differential effects between a calcium channel blocker and a diuretic when used in combination with angiotensin II receptor blocker on central aortic pressure in hypertensive patients.

Hypertension (Dallas, Tex. : 1979) 20091001

Central blood pressure under angiotensin and calcium channel blockade.

Hypertension (Dallas, Tex. : 1979) 20091001

Impact of azelnidipine treatment on left ventricular diastolic performance in patients with hypertension and mild diastolic dysfunction: multi-center study with echocardiography.

Hypertension research : official journal of the Japanese Society of Hypertension 20091001

Combination of chronic exercise and antihypertensive therapy enhances renoprotective effects in rats with renal ablation.

American journal of hypertension 20091001

Azelnidipine and amlodipine anti-coronary atherosclerosis trial in hypertensive patients undergoing coronary intervention by serial volumetric intravascular ultrasound analysis in Juntendo university (ALPS-J).

Cardiovascular drugs and therapy 20091001

Inhibitory effects of a dihydropyridine calcium channel blocker on renal injury in aldosterone-infused rats.

Journal of hypertension 20090901

Mechanism of diastolic stiffening of the failing myocardium and its prevention by angiotensin receptor and calcium channel blockers.

Journal of cardiovascular pharmacology 20090701

Combination use of immune complexes and a Ca2(+) channel blocker azelnidipine enhances interleukin-12 p40 secretion without T helper type 17 cytokine secretion in human monocyte-derived dendritic cells.

Clinical and experimental immunology 20090601

Therapeutic strategy for ischemic stroke.

Neurochemical research 20090401

Chronotropic effects of azelnidipine, a slow- and long-acting dihydropyridine-type calcium channel blocker, in anesthetized dogs: a comparison with amlodipine.

Journal of cardiovascular pharmacology 20090401

Azelnidipine inhibits aldosterone synthesis and secretion in human adrenocortical cell line NCI-H295R.

European journal of pharmacology 20090301

Prevention of vascular injury by combination of an AT1 receptor blocker, olmesartan, with various calcium antagonists.

American journal of hypertension 20090201

Comparative effects of olmesartan and azelnidipine on atrial structural remodeling in spontaneously hypertensive rats.

Pharmacology 20090101

Gene and stem cell therapy in ischemic stroke.

Cell transplantation 20090101

Comparative pharmacodynamics of olmesartan and azelnidipine in patients with hypertension: a population pharmacokinetic/pharmacodynamic analysis.

Drug metabolism and pharmacokinetics 20090101

Beneficial effects of combination therapy with olmesartan and azelnidipine in murine polycystic kidneys.

Kidney & blood pressure research 20090101

Azelnidipine decreases plasma matrix metalloproteinase-9 levels after endovascular abdominal aortic aneurysm repair.

The Kurume medical journal 20090101

Enhanced pulsatile pressure accelerates vascular smooth muscle migration: implications for atherogenesis of hypertension.

Cardiovascular research 20081201

Renoprotective effect of azelnidipine in rats.

Biological & pharmaceutical bulletin 20081201

Azelnidipine decreases sympathetic nerve activity via antioxidant effect in the rostral ventrolateral medulla of stroke-prone spontaneously hypertensive rats.

Journal of cardiovascular pharmacology 20081201

Hemodynamic influences of azelnidipine, a novel calcium channel blocker, on cerebral circulation in hypertensive patients with ischemic white matter lesions.

Hypertension research : official journal of the Japanese Society of Hypertension 20081201

Additional renoprotective effects of azelnidipine combined with angiotensin receptor blockers in patients with diabetic nephropathy.

Clinical nephrology 20081101

Determination of azelnidipine by LC-ESI-MS and its application to a pharmacokinetic study in healthy Chinese volunteers.

Die Pharmazie 20080801

In half of hypertensive diabetics, co-administration of a calcium channel blocker and an angiotensin-converting enzyme inhibitor achieved a target blood pressure of <130/80 mmHg: the azelnidipine and temocapril in hypertensive patients with type 2 diabetes (ATTEST) study.

Hypertension research : official journal of the Japanese Society of Hypertension 20080801

In vivo imaging of renal redox status during azelnidipine treatment.

Hypertension research : official journal of the Japanese Society of Hypertension 20080801

Combination therapy with renin-angiotensin system inhibitors and the calcium channel blocker azelnidipine decreases plasma inflammatory markers and urinary oxidative stress markers in patients with diabetic nephropathy.

Hypertension research : official journal of the Japanese Society of Hypertension 20080601

Effects of azelnidipine on the autonomic functions and its influence on arterial stiffness and endothelial functions.

Journal of cardiology 20080401

Spectroscopic studies on the interaction of azelnidipine with bovine serum albumin.

International journal of pharmaceutics 20080303

Effects of antihypertensive drugs and exercise training on insulin sensitivity in spontaneously hypertensive rats.

Hypertension research : official journal of the Japanese Society of Hypertension 20080301

Azelnidipine has anti-atherosclerotic effects independent of its blood pressure-lowering actions in monkeys and mice.

Atherosclerosis 20080101

Calcium channel blocker, azelnidipine, reduces lipid hydroperoxides in patients with type 2 diabetes independent of blood pressure.

Endocrine journal 20071201

Prevention of neuronal damage by calcium channel blockers with antioxidative effects after transient focal ischemia in rats.

Brain research 20071024

Antioxidative effects of azelnidipine on mesangial cell proliferation induced by highly concentrated insulin.

European journal of pharmacology 20070719

Enantioselective determination of azelnidipine in human plasma using liquid chromatography-tandem mass spectrometry.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070601

Azelnidipine reduces urinary protein excretion and urinary liver-type fatty acid binding protein in patients with hypertensive chronic kidney disease.

The American journal of the medical sciences 20070601

Effects of new calcium channel blocker, azelnidipine, and amlodipine on baroreflex sensitivity and ambulatory blood pressure.

Journal of cardiovascular pharmacology 20070601

Effect of benidipine on simvastatin metabolism in human liver microsomes.

Drug metabolism and pharmacokinetics 20070601

The long-acting Ca2+-channel blocker azelnidipine prevents left ventricular remodeling after myocardial infarction.

Journal of pharmacological sciences 20070401

Azelnidipine attenuates cardiovascular and sympathetic responses to air-jet stress in genetically hypertensive rats.

Hypertension research : official journal of the Japanese Society of Hypertension 20070401

Azelnidipine inhibits H2O2-induced cell death in neonatal rat cardiomyocytes.

Cardiovascular drugs and therapy 20070201

Determination of azelnidipine in human plasma by liquid chromatography-electrospray ionization-mass spectrometry.

Journal of pharmaceutical and biomedical analysis 20070117

Long-acting calcium channel blocker, azelnidipine, increases endothelial nitric oxide synthase in the brain and inhibits sympathetic nerve activity.

Clinical and experimental hypertension (New York, N.Y. : 1993) 20070101

Effects of calcium channel blocker azelnidipine on experimental abdominal aortic aneurysms.

Surgery today 20070101

Clinical study with azelnidipine in patients with essential hypertension. Antiarteriosclerotic and cardiac hypertrophy-inhibitory effects and influence on autonomic nervous activity.

Arzneimittel-Forschung 20070101

SDF-1-induced adhesion of monocytes to vascular endothelium is modulated by azelnidipine via protein kinase C inhibition.

European journal of pharmacology 20061215

Calcium channel blocker azelnidipine reduces glucose intolerance in diabetic mice via different mechanism than angiotensin receptor blocker olmesartan.

The Journal of pharmacology and experimental therapeutics 20061201

Tilting-induced decrease in systolic blood pressure in bedridden hypertensive elderly inpatients: effects of azelnidipine.

Hypertension research : official journal of the Japanese Society of Hypertension 20061201

Simultaneous determination of azelnidipine and two metabolites in human plasma using liquid chromatography-tandem mass spectrometry.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20061121

The actions of azelnidipine, a dihydropyridine-derivative Ca antagonist, on voltage-dependent Ba2+ currents in guinea-pig vascular smooth muscle.

British journal of pharmacology 20061101

The calcium-channel blocker, azelnidipine, enhances the inhibitory action of AT1 receptor blockade on ischemic brain damage.

Journal of hypertension 20061001

Enhancement of cardiac oxidative stress by tachycardia and its critical role in cardiac hypertrophy and fibrosis.

Journal of hypertension 20061001

Azelnidipine down-regulates renal angiotensin-converting enzyme and mineralocorticoid receptor mRNA in diabetic hypertensive rats.

Journal of pharmacological sciences 20061001

Efficacy of azelnidipine on home blood pressure and pulse rate in patients with essential hypertension: comparison with amlodipine.

Hypertension research : official journal of the Japanese Society of Hypertension 20061001

Azelnidipine, a new calcium channel blocker, inhibits endothelial inflammatory response by reducing intracellular levels of reactive oxygen species.

European journal of pharmacology 20060928

A third-generation, long-acting, dihydropyridine calcium antagonist, azelnidipine, attenuates stent-associated neointimal formation in non-human primates.

Journal of hypertension 20060901

[Novel actions of calcium channel blockers].

Nihon rinsho. Japanese journal of clinical medicine 20060801

Effects of calcium channel blockade on angiotensin II-induced peritubular ischemia in rats.

The Journal of pharmacology and experimental therapeutics 20060301

Comparative effects of azelnidipine and other Ca2+-channel blockers on the induction of inducible nitric oxide synthase in vascular smooth muscle cells.

Journal of cardiovascular pharmacology 20060201

The newly developed calcium antagonist, azelnidipine, increases drain volume in continuous ambulatory peritoneal dialysis patients.

Advances in peritoneal dialysis. Conference on Peritoneal Dialysis 20060101

Azelnidipine, a new long-acting calcium-channel blocker, inhibits tumour necrosis factor-alpha-induced monocyte chemoattractant protein-1 expression in endothelial cells.

The Journal of international medical research 20060101

Effects of a new calcium channel blocker, azelnidipine, on systemic hemodynamics and renal sympathetic nerve activity in spontaneously hypertensive rats.

Hypertension research : official journal of the Japanese Society of Hypertension 20051201

Effect of combination of calcium antagonist, azelnidipine, and AT1 receptor blocker, olmesartan, on atherosclerosis in apolipoprotein E-deficient mice.

Journal of hypertension 20050701

Effect of azelnidipine on angiotensin II-mediated growth-promoting signaling in vascular smooth muscle cells.

Molecular pharmacology 20050501

Unique atheroprotective property of azelnidipine, a dihydropyridine-based calcium antagonist.

Medical hypotheses 20050101

Renoprotective effects of azelnidipine, a dihydropyridine-based calcium antagonist in advanced glycation end product (AGE)-injected rats.

International journal of tissue reactions 20050101

Azelnidipine, a dihydropyridine-based calcium antagonist, inhibits angiotensin II-induced oxidative stress generation and downregulation of pigment epithelium-derived factor mRNA levels in microvascular endothelial cells.

Drugs under experimental and clinical research 20050101

Additive beneficial effects of the combination of a calcium channel blocker and an angiotensin blocker on a hypertensive rat-heart failure model.

Hypertension research : official journal of the Japanese Society of Hypertension 20041001

Azelnidipine, a newly developed long-acting calcium antagonist, inhibits tumor necrosis factor-alpha-induced interleukin-8 expression in endothelial cells through its anti-oxidative properties.

Journal of cardiovascular pharmacology 20040501

Biliary excretion of azelnidipine, a calcium antagonist, in rats.

Journal of gastroenterology and hepatology 20040401

Calcium channel blocker azelnidipine enhances vascular protective effects of AT1 receptor blocker olmesartan.

Hypertension (Dallas, Tex. : 1979) 20040201

Antioxidant effect of a new calcium antagonist, azelnidipine, in cultured human arterial endothelial cells.

The Journal of international medical research 20040101

[Pharmacological profiles and clinical effects of azelnidipine, a long-acting calcium channel blocker].

Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20031201

Azelnidipine and amlodipine: a comparison of their pharmacokinetics and effects on ambulatory blood pressure.

Hypertension research : official journal of the Japanese Society of Hypertension 20030301

Azelnidipine. CS 905, Calblock, RS 9054.

Drugs in R&D 20030101

Azelnidipine.

Drugs 20030101

Combination therapy with an angiotensin-converting enzyme (ACE) inhibitor and a calcium antagonist: beyond the renoprotective effects of ACE inhibitor monotherapy in a spontaneous hypertensive rat with renal ablation.

Hypertension research : official journal of the Japanese Society of Hypertension 20020501

Antihypertensive effects of CS-905, a novel dihydropyridine Ca++ channel blocker.

Japanese journal of pharmacology 19890901